Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Slightly Bullish +15

Boston Scientific Stock (BSX) Opinions on Recent Analyst Downgrades - Quiver Quantitative

AI-generated analysis

πŸ“‰ Analyst sentiment turned negative after a price target cut linked to softer demand for the Watchman device and bundling pressures.

πŸ“Š Q1 2026 revenues surged 11.58% year-over-year to reach $5.2 billion, demonstrating strong underlying business growth.

🏦 Major institutional investors like FMR LLC reduced holdings by 23.8%, while Wellington Management increased positions by 94% in Q1 2026.

πŸ’Ό CEO Michael Mahoney sold 160,901 shares worth approximately $15 million over the past six months.

πŸ“ˆ Multiple Wall Street firms including BTIG and Needham maintain 'Buy' ratings on the stock.

🎯 Recent analyst price targets range from $64 to $74, with a median target of $77.5.

⚠️ Market concerns persist regarding recent product recalls and regional pacemaker issues affecting the stock's technical chart.

πŸ’° The company generated $23.7 million in award payments over the last year, primarily from TheraspHERE Y-90 products.

Bullish Signals
  • Q1 2026 revenue increased by 11.58% to $5.2 billion compared to the prior year.
  • Wellington Management Group LLP added 9.1 million shares (+94.0%) to its portfolio in Q1 2026.
  • Franklin Resources Inc added 8.8 million shares (+155.4%) to its portfolio in Q1 2026.
  • Two Sigma Investments, LP increased holdings by 6.9 million shares (+280.8%) in Q1 2026.
  • Three major firms (BTIG, Needham, Truist Securities) issued 'Buy' ratings on the stock recently.
  • Members of Congress have made five purchases and zero sales of BSX stock in the past six months.
Risk Factors
  • An analyst lowered price targets citing softer demand for the Watchman device and bundling pressures.
  • The stock is trading near multi-year lows with ongoing pressure from put sellers.
  • Recent recalls and regional pacemaker issues are contributing to a cautious market tone.
  • FMR LLC removed 23.1 million shares (-23.8%) from its portfolio in Q1 2026.
  • Capital World Investors reduced their position by 11.8 million shares (-43.6%) in Q1 2026.
  • CEO Michael Mahoney sold 160,901 shares for an estimated $15 million over the last six months.
Full Analysis
Boston Scientific (BSX) faces mixed market sentiment following an analyst downgrade driven by softer demand for its Watchman device and concerns over procedure bundling. The stock exhibits technical weakness near multi-year lows, with investors citing recent recalls and regional pacemaker issues as contributing factors to a cautious outlook despite the broader medtech sector showing tentative signs of recovery. Despite the negative chatter, fundamental financial performance remains robust, with Q1 2026 revenues reaching $5.2 billion, representing an 11.58% year-over-year increase. Institutional investor activity is highly polarized in Q1 2026, with major firms like FMR LLC and Capital World Investors significantly reducing positions, while Wellington Management and Franklin Resources aggressively increased their holdings. Insider trading data reveals a split narrative: CEO Michael Mahoney sold over $15 million in shares, whereas other executives and members of Congress have been net buyers. Wall Street consensus remains cautiously optimistic with multiple buy ratings from firms like BTIG and Needham, though recent price targets from analysts at Stifel and Jefferies hover around the low-to-mid $60s. Analyst price targets for BSX currently range from $64 to $74, with a median target of $77.5 set over the last six months. The company continues to generate significant award payments related to its TheraspHERE Y-90 radiopharmaceuticals, highlighting ongoing revenue streams in specialized medical treatments.